Press release
Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)
Ewing Sarcoma Pipeline
Key Takeaways from the Ewing Sarcoma Pipeline Report
• DelveInsight's Ewing Sarcoma pipeline report depicts a robust space with 25+ Ewing Sarcoma companies working to develop 25+ pipeline therapies for Ewing Sarcoma treatment.
• The leading Ewing Sarcoma Companies working in the market include Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Promising Ewing Sarcoma Pipeline Therapies in the various stages of development includes Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.
• April 2024:- Shanghai Pharmaceuticals Holding Co., Ltd- The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma：a Phase II Clinical Trial in China. This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).
• April 2024:- Eli Lilly and Company- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma. The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
Request a sample and discover the recent advances in Ewing Sarcoma Treatment Drugs @ Ewing Sarcoma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Ewing Sarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ewing Sarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ewing Sarcoma clinical trial landscape.
Ewing Sarcoma Overview
Ewing sarcoma is the second most common primary malignant bone tumor, mostly affecting adolescents in the second decade of their life, and it is a highly metastatic class of sarcoma. Despite the use of radiotherapy or surgery, historically, an estimated 85% to 90% of patients died within a few months from a metastasis.
Find out more about Ewing Sarcoma Treatment Landscape @ Drugs for Ewing Sarcoma Treatment- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Ewing Sarcoma Emerging Drugs Profile
• Vigil: Gradalis
• ONCT216: Oncternal Therapeutics
• SP-2577: Salarius Pharmaceuticals
Ewing Sarcoma Pipeline Therapeutics Assessment
There are approx. 25+ Ewing Sarcoma companies which are developing the Ewing Sarcoma therapies. The Ewing Sarcoma companies which have their Ewing Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Gradalis.
DelveInsight's Ewing Sarcoma pipeline report covers around 25+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Ewing Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Ewing Sarcoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Learn more about the emerging Ewing Sarcoma Pipeline Therapies @ Ewing Sarcoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Ewing Sarcoma Pipeline Report
• Coverage- Global
• Ewing Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ewing Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ewing Sarcoma Companies- Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Ewing Sarcoma Pipeline Therapies- Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.
Dive deep into rich insights for new drugs for Ewing Sarcoma treatment, Visit @ Ewing Sarcoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Ewing Sarcoma Executive Summary
3. Ewing Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ewing Sarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Vigil: Gradalis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ONCT216: Oncternal Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SP-2577: Salarius Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. CLR 131: Cellectar Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ewing Sarcoma Companies
21. Ewing Sarcoma Key Products
22. Ewing Sarcoma Unmet Needs
23. Ewing Sarcoma Market Drivers and Barriers
24. Ewing Sarcoma Future Perspectives and Conclusion
25. Ewing Sarcoma Analyst Views
26. Ewing Sarcoma Key Companies
27. Appendix
For further information on the Ewing Sarcoma pipeline therapeutics, reach out to Ewing Sarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Published Links-
https://www.hoyolab.com/article/27093025
https://www.kfz-betrieb.vogel.de/community/user/ybhardwaj
https://pad.funkwhale.audio/s/z1sjb2E6Z
https://swaay.com/u/daviddollareusa/about/
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/
https://thelittlenet.com/dennydonesgerman
http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Updated) here
News-ID: 3468955 • Views: …
More Releases from DelveInsight Business Research LLP
Polycystic Kidney Disease Pipeline Outlook 2025: Insights Into Therapies, Resear …
DelveInsight's, "Polycystic Kidney Diseases Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Polycystic Kidney Diseases pipeline landscape. It covers the Polycystic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Polycystic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
Chronic Obstructive Pulmonary Disease Treatment Market Size Report 2034: Insight …
DelveInsight's "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology and the COPD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Chronic Obstructive Pulmonary Disease Market Share @ Chronic Obstructive Pulmonary Disease Market Outlook- https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
Dry Eye Syndrome Treatment Market Size Report 2034: Insights Into Therapies, Res …
DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the DED, historical and forecasted epidemiology as well as the DED market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Dry Eye Syndrome Market Share @ Dry Eye Syndrome Market Outlook- https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
Major Depressive Disorder Pipeline Outlook 2025: Insights Into Therapies, Resear …
DelveInsight's "Major Depressive Disorder Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover…
More Releases for Ewing
Pioneering Advances Propel the Ewing Sarcoma Drugs Market to New Heights
The global Ewing sarcoma drugs market is poised for remarkable growth over the next decade, driven by scientific breakthroughs, robust pipeline portfolios, and an increasing focus on targeted therapies. Once a niche segment within oncology, treatments for Ewing sarcoma-an aggressive bone and soft-tissue tumor predominantly affecting children, adolescents, and young adults-are rapidly evolving from broad-spectrum chemotherapeutic regimens to precision medicines that promise improved outcomes and reduced toxicity.
The global Ewing sarcoma…
Mad Max Publishing Announces Newest Best-Selling Author Hunter Ewing
Image: https://www.abnewswire.com/upload/2025/04/6dbb7a2237180d135128f8603075b1f4.jpg
Doral, FL - Mad Max Publishing, announced its newest bestselling author Hunter Ewing, who's recently released book, "The Playmaker" quickly climbed the charts to become a number one bestseller.
Published, Promoted and Reached #1 National Bestseller on Amazon.
Hunter Ewing is the #1 Best-Selling Author of The Playmaker , a powerful guide that equips business owners with branding strategies to rise above their competition and dominate their niche. A former college…
Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Compani …
DelveInsight's, "Ewing Sarcoma Pipeline Insights" report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Ewing Sarcoma Drugs Market is Booming Worldwide with CAGR of 5.6%
The global and Middle East Africa Ewing Sarcoma Drugs Market is the most recent research report from USD Analytics that analyses market risk side data, highlights opportunities, and uses that data to support tactical as well as strategic decision-making. A thorough investigation was conducted to provide the most recent information on the market's key characteristics for Ewing Sarcoma Drugs. Regarding revenue size, production, CAGR, consumption, gross margin, pricing, and other…
Global Ewing Sarcoma Drugs Market Size, Share, Growth & Forecast 2023-2032
In the forecasted period from 2022 to 2030, the market for medications to treat ewing sarcoma is anticipated to expand at a CAGR of 5.5%. The rise in ewing sarcoma cases, more knowledge of the disease and its treatments, and the introduction of innovative therapeutics for the illness are all factors contributing to the market's expansion. Based on type, application, and location, the market for ewing sarcoma medications is divided…
Ewing Sarcoma Market (2019-2028) Overview with Size, Patients Population, Total …
Ewing Sarcoma Market Synopsis:
Global Ewing Sarcoma Market Insights, Epidemiology and Market Forecast studies the present scenario of market (with the base year being 2018), Key Cross Competition, and the growth prospects of global Ewing Sarcoma market for 2018-2028
definition of Ewing Sarcoma:
Ewing sarcoma is a malignant small, round, blue cell tumor. It is a disease in which cancer cells are found in the bone or in soft tissue. The most common…
